Bioactive highly porous and injectable scaffolds controlling stem cell recruitment, proliferation and differentiation and enabling angiogenesis for cardiovascular engineered tissues
Congenital and acquired heart diseases are the leading causes of morbidity and mortality in the developed countries. Successful treatment of cardiovascular diseases is limited in many situations by the lack of suitable autologous tissue to restore injured muscle, heart valves, and vascular conduits. This results in a part of the heart actually dying since the organ cannot repair itself.
The improvement of new therapies for treating cardiovascular conditions is the topic of BIOSCENT project, and the main objective is the development of innovative polymeric scaffolds able to guide tissue formation from dissociated stem cells and suitable for creating autologous cardiovascular replacements.
The BIOSCENT consortium is composed of 15 highly esteemed participants, including both industrial and academic researchers: University of Pisa (IT), Czech Academy of Experimental Medicine (CZ), Friedrich-Alexander-Universitat Erlangen Nurnberg (GE), Petru Poni Institute of Macromolecular Chemistry(RO), Inspiralia (SP), University of Manchester (UK), Politecnico of Torino (IT), Hannover Medical School (DE), Hubrecht Laboratory (NL); University of Parma (IT), IMM Research (FR), Chempilots (DK), Cambridge Research Biochemicals (UK), Immunological and Biochemical test systems (DE) and the Europe´s largest cardiovascular company, SORIN (IT).
Inspiralia is the technical coordinator of the project together with the University of Pisa. Their main role is the development of new natural-synthetic polymer blends for heart valve scaffolds and cardiac patches via the collaboration of the Advanced Materials and Computational Engineering Groups.
For more information please visit the website of BIOSCENT.